Letterio Politi to Rituximab
This is a "connection" page, showing publications Letterio Politi has written about Rituximab.
Connection Strength
0.274
-
Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, Torri V, Fox CP, Ros?e PL, Schorb E, Ambrosetti A, Roth A, Hemmaway C, Ferrari A, Linton KM, Rud? R, Binder M, Pukrop T, Balzarotti M, Fabbri A, Johnson P, G?rl?v JS, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause SW, Levis A, Schmoll HJ, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016 May; 3(5):e217-27.
Score: 0.125
-
Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, Celico C, Falautano M, Nonis A, La Ros?e P, Binder M, Fabbri A, Ilariucci F, Krampera M, Roth A, Hemmaway C, Johnson PW, Linton KM, Pukrop T, G?rl?v JS, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Zanni M, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Thurner L, Cabras G, Pennese E, Ponzoni M, Deckert M, Politi LS, Finke J, Ferranti A, Cozens K, Burger E, Ielmini N, Cavalli F, Zucca E, Illerhaus G. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022 07; 36(7):1870-1878.
Score: 0.048
-
Ferreri AJM, Calimeri T, Ponzoni M, Curnis F, Conte GM, Scarano E, Rrapaj E, De Lorenzo D, Cattaneo D, Fallanca F, Nonis A, Foppoli M, Lopedote P, Citterio G, Politi LS, Sassone M, Angelillo P, Guggiari E, Steffanoni S, Tarantino V, Ciceri F, Bordignon C, Anzalone N, Corti A. Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. Blood Adv. 2020 08 11; 4(15):3648-3658.
Score: 0.042
-
Ferreri AJM, Calimeri T, Conte GM, Cattaneo D, Fallanca F, Ponzoni M, Scarano E, Curnis F, Nonis A, Lopedote P, Citterio G, Politi LS, Foppoli M, Girlanda S, Sassone M, Perrone S, Cecchetti C, Ciceri F, Bordignon C, Corti A, Anzalone N. R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-a in primary CNS lymphoma. Blood. 2019 07 18; 134(3):252-262.
Score: 0.039
-
Madaschi S, Rossini A, Formenti I, Lampasona V, Marzoli SB, Cammarata G, Politi LS, Martinelli V, Bazzigaluppi E, Scavini M, Bosi E, Lanzi R. Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review. Endocr Pract. 2010 Jul-Aug; 16(4):677-85.
Score: 0.021